China has the second largest healthcare expenditure in the world, behind only the US. The country’s healthcare sector was one of the best-performing equity classes globally in the first half of 2020, despite market turmoil. Nonetheless, problems such as quality concerns and geopolitical headwinds add to the challenges as China struggles to promote innovation in the industry while keeping costs in check. The outbreak of Covid-19 has further complicated the situation with structural shifts in the global supply chain of healthcare products, bringing both risks and opportunities to investors.
Get a comprehensive industry review and insights on Covid-19 induced market shifts in the China Healthcare Report, brought to you by SCMP Research. Leveraging the South China Morning Post
’s unmatched access into China, the report includes:
- An overview of China’s healthcare industry
- Developments by segment with deep dive case studies and the latest advances and predictions, including opportunities, bottlenecks and risks
- Segments covered include: pharmaceuticals, biotech, medical devices and supplies, healthcare service providers, and healthcare technology
- Companies featured in the case studies include industry leaders and innovators such as 111, Inc., Zai Lab, Venus Medtech, and more
The report also comes with access to 6 closed-door webinars led by China healthcare’s most influential C-suite executives.
We’d like to invite you to sign up for an exclusive 50% early bird discount. You will be entitled to the early bird discount if you register before 12 August, 2020. After registering, you are not obliged to purchase the report if you subsequently decide not to proceed with the purchase.
By registering for the discount you acknowledge that you have read and agreed to be bound by our terms and conditions